Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809919 | 1.00 | CYP1A2 (0.37) | CYP1A2CYP1A1CYP1B1CYP2B6CA1 | |
| SCHEMBL7534013 | 0.76 | MAOA (0.41) | CYP1A2CYP1A1CYP1B1CYP2B6KMT2A | |
| SCHEMBL4536799 | 0.74 | CYP2B6 (0.47) | CYP1A2CYP1A1CYP1B1CYP2B6KMT2A | |
| SCHEMBL1010575 | 0.73 | TNKS (0.37) | CYP1A2CYP1A1CYP1B1CYP2B6KMT2A | |
| SCHEMBL20623232 | 0.73 | MAPT (0.38) | KMT2A | |
| SCHEMBL3624225 | 0.73 | CYP2B6 (0.40) | CYP1A2CYP1A1CYP1B1CYP2B6KMT2A | |
| SCHEMBL29384225 | 0.73 | TRPM4 (0.43) | CYP1A2CYP1A1CYP1B1CYP2B6CA1 | |
| SCHEMBL1063519 | 0.72 | CA1 (0.36) | CYP1A2CYP1A1CYP1B1CYP2B6CA1 | |
| SCHEMBL1011282 | 0.72 | CA1 (0.36) | CYP2B6CA1 | |
| SCHEMBL8234878 | 0.72 | MAOA (0.41) | CYP1A2CYP1A1CYP1B1CYP2B6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031597-B | Polysubstituted dibenzochromene compound and application thereof | 江苏视科新材料股份有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-114031596-B | Dibenzo chromene photochromic compound and application thereof | 江苏视科新材料股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114031598-B | Preparation method of polysubstituted dibenzochromene compound | 江苏视科新材料股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114031599-B | Preparation method of dibenzochromene photochromic compound | 江苏视科新材料股份有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-114031594-B | Dibenzo chromene compound and application thereof | 江苏视科新材料股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-114057682-B | Preparation method of dibenzochromene compound | 江苏视科新材料股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-114031597-B | Polysubstituted dibenzochromene compound and application thereof | 江苏视科新材料股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-114031597-B | Polysubstituted dibenzochromene compound and application thereof | 江苏视科新材料股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-114031597-B | Polysubstituted dibenzochromene compound and application thereof | 江苏视科新材料股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-114031598-B | Preparation method of polysubstituted dibenzochromene compound | 江苏视科新材料股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114031596-B | Dibenzo chromene photochromic compound and application thereof | 江苏视科新材料股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114031598-B | Preparation method of polysubstituted dibenzochromene compound | 江苏视科新材料股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114031598-B | Preparation method of polysubstituted dibenzochromene compound | 江苏视科新材料股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-8404869-B2 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20100234453-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | KT & G CO., LTD. (KR) | 2010-09-16 | — | — | US | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| EP-2137175-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | Mazence Inc. (KR) | 2009-12-30 | — | — | EP | disclosed |
| EP-2094262-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | Mazence Inc. (KR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008133441-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008066296-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234453-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | SLC10A2, SI, ABCB11 | CYP1A2 134/4885CYP1A1 114/4885CYP1B1 144/4885 |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | CYP1A2 166/4885CYP1A1 47/4885CYP1B1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.